Literature DB >> 19161536

Cyclooxygenase-2 expression on urothelial and inflammatory cells of cystoscopic biopsies and urine cytology as a possible predictive marker for bladder carcinoma.

Mona Moussa1, Zeinab Omran, Mona Nosseir, Abeya Lotfy, Tarek Swellam.   

Abstract

Cyclooxygenase-2 (COX-2) is a key inducible enzyme involved in the production of prostaglandins. It contributes to human carcinogenesis by various mechanisms. The aim of the current study was to elucidate the possible involvement of COX-2 in human bladder carcinoma by examining its expression on both urothelial and inflammatory cells in tissue biopsies and urine cytology samples of different urinary bladder lesions. A total of 65 patients were included in the study and were selected from cases admitted to Urology Department, Theodor Bilharz Research Institute (TBRI), Giza, Egypt. They represented seven control cases with almost normal-looking bladder tissue; pure chronic cystitis (n=12); premalignant lesions (18) in the form of squamous metaplasia (n=8) or urothelial dysplasia (n=10) as well as transitional cell carcinoma (TCC) (n=18), and squamous cell carcinoma (SqCC) (n=10). Immunohistochemistry of formalin-fixed, paraffin-embedded tissue sections and urine cytology samples was performed for all cases using COX-2 (H-62): sc-7951, a rabbit polyclonal antibody. The study revealed positive COX-2 expression on the urothelial and inflammatory cells of cystoscopic biopsies from all cases of pure chronic cystitis, squamous metaplasia and SqCC compared with 42.8% and 71.4% of normal controls, respectively. The score of urothelial COX-2 expression was sequentially up-regulated from normal to chronic cystitis (either pure or associated with premalignant changes) (p<0.05) to malignant changes (p<0.05). However, the inflammatory cellular expression was down-regulated with malignant transformation compared with chronic cystitis (p<0.05). In TCC, COX-2 was over-expressed on both urothelial and inflammatory cells in advanced tumors. Urine cytology samples were positive for COX-2 in a comparable manner to that observed in cystoscopic biopsies. Accordingly, the results of the current study have provided new information in two aspects: First, is the possibility of using the differential COX-2 expression on both inflammatory and urothelial cells as markers for premalignant or malignant transformation; second, besides cystoscopy, urine cytology was found to have a high sensitivity for COX-2 expression and hence proved to be valuable in malignancy as a non-invasive substitute for cystoscopy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19161536     DOI: 10.1111/j.1600-0463.2008.00014.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  5 in total

1.  COX2/mPGES1/PGE2 pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells.

Authors:  Victor Prima; Lyudmila N Kaliberova; Sergey Kaliberov; David T Curiel; Sergei Kusmartsev
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-17       Impact factor: 11.205

2.  Increased COX-2 Immunostaining in Urothelial Carcinoma of the Urinary Bladder Is Associated with Invasiveness and Poor Prognosis.

Authors:  Basim Al-Maghrabi; Wafaey Gomaa; Mohammed Abdelwahed; Jaudah Al-Maghrabi
Journal:  Anal Cell Pathol (Amst)       Date:  2019-04-21       Impact factor: 2.916

Review 3.  Systematic review of the potential role of cannabinoids as antiproliferative agents for urological cancers.

Authors:  Shreyas Gandhi; Gaurav Vasisth; Anil Kapoor
Journal:  Can Urol Assoc J       Date:  2017-04-11       Impact factor: 1.862

4.  Immunohistochemical expression of COX2 and iNOS in bladder cancer and its association with urinary schistosomiasis among Sudanese patients.

Authors:  Hassan Elsiddig Hassan; Ahmed Abdel Badie Mohamed; Amel Omer Bakhiet; Hussain Gadelkarim Ahmed
Journal:  Infect Agent Cancer       Date:  2013-02-15       Impact factor: 2.965

5.  Lower cyclooxygenase-2 expression is associated with recurrence of solitary non-muscle invasive bladder carcinoma.

Authors:  Tomislav Tadin; Kristian Krpina; Sanja Stifter; Emina Babarović; Zeljko Fučkar; Nives Jonjić
Journal:  Diagn Pathol       Date:  2012-11-05       Impact factor: 2.644

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.